Proteomics analysis identifies potential drug targets for aggressive human cancers
Researchers identified proteomic signatures associated with clinical measures of aggressive disease for each of the seven cancer types studied.
Read moreResearchers identified proteomic signatures associated with clinical measures of aggressive disease for each of the seven cancer types studied.
Read moreInhibiting MAPK4 simultaneously inactivated both androgen receptor and AKT and stopped cancer growth in animal models.
Read moreBaylor College of Medicine researchers extend the life and effectiveness of off-the-shelf, cancer-fighting immune T cells.
Read moreClinical trial of novel personalized CAR T cell immunotherapy provides clues into what mediated exceptional patient recovery.
Read moreDespite major advances in cancer therapy, conventional cancer treatments continue to be associated with devastating side effects for patients and are not always curative. In
Read more